Prospective Phase II Trial of Prognostication by
PET
molecular imaging
neuroendocrine neoplasms
prognosis
urokinase plasminogen activator receptor (uPAR)
Journal
Journal of nuclear medicine : official publication, Society of Nuclear Medicine
ISSN: 1535-5667
Titre abrégé: J Nucl Med
Pays: United States
ID NLM: 0217410
Informations de publication
Date de publication:
09 2022
09 2022
Historique:
received:
14
09
2021
revised:
12
01
2022
pubmed:
22
1
2022
medline:
13
10
2022
entrez:
21
1
2022
Statut:
ppublish
Résumé
The clinical course for patients with neuroendocrine neoplasms (NENs) ranges from indolent to highly aggressive. Noninvasive tools to improve prognostication and guide decisions on treatment are warranted. Expression of urokinase plasminogen activator receptor (uPAR) is present in many cancer types and associated with a poor outcome. Therefore, using an in-house-developed uPAR PET tracer [
Identifiants
pubmed: 35058319
pii: jnumed.121.263177
doi: 10.2967/jnumed.121.263177
pmc: PMC9454472
doi:
Substances chimiques
Gallium Radioisotopes
0
Heterocyclic Compounds, 1-Ring
0
Receptors, Urokinase Plasminogen Activator
0
1,4,7-triazacyclononane-N,N',N''-triacetic acid
56491-86-2
Types de publication
Clinical Trial, Phase II
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
1371-1377Informations de copyright
© 2022 by the Society of Nuclear Medicine and Molecular Imaging.
Références
Proteomics. 2019 Nov;19(21-22):e1900026
pubmed: 31402590
Cell. 2011 Mar 4;144(5):646-74
pubmed: 21376230
J Nucl Med. 2021 Jun 1;62(6):808-815
pubmed: 33067340
PLoS One. 2012;7(12):e51862
pubmed: 23251644
Am J Nucl Med Mol Imaging. 2016 Jan 28;6(1):59-72
pubmed: 27069766
N Engl J Med. 2017 Jan 12;376(2):125-135
pubmed: 28076709
J Nucl Med. 2020 Oct;61(10):1491-1497
pubmed: 32111685
J Nucl Med. 2017 Mar;58(3):379-386
pubmed: 27609788
Nucl Med Biol. 2012 Oct;39(7):962-9
pubmed: 22739362
Int J Mol Sci. 2021 Apr 16;22(8):
pubmed: 33923400
Front Oncol. 2018 Feb 12;8:24
pubmed: 29484286
Mol Pharm. 2014 Aug 4;11(8):2796-806
pubmed: 24955765
Endocr Relat Cancer. 2020 Mar;27(3):R67-R77
pubmed: 31846429
Eur J Cancer. 2009 Jan;45(2):228-47
pubmed: 19097774
Nucl Med Biol. 2012 May;39(4):560-9
pubmed: 22172391
J Nucl Med. 2021 Mar;62(3):354-359
pubmed: 32764119
Int J Mol Sci. 2021 Apr 22;22(9):
pubmed: 33921923
J Nucl Med. 2021 Nov;62(11):1564-1570
pubmed: 33637589
Neuroendocrinology. 2017 Feb 17;105(3):310-319
pubmed: 28222443
Clin Cancer Res. 2010 Feb 1;16(3):978-85
pubmed: 20103666
J Nucl Med. 2016 Dec;57(12):1851-1857
pubmed: 27469355
Bone Res. 2020 Apr 17;8:18
pubmed: 32337090
Br J Cancer. 2013 Mar 5;108(4):766-70
pubmed: 23412098
J Clin Med. 2020 May 31;9(6):
pubmed: 32486367
Acta Oncol. 2021 Jul;60(7):931-941
pubmed: 33999752
Curr Drug Targets. 2011 Nov;12(12):1711-28
pubmed: 21707479